source
- Regeneron immunotherapy combo comes up short in melanoma trialA two-drug regimen of Regeneron’s fianlimab and Libtayo didn’t significantly outperform Keytruda in a late-stage study, a finding that surprised Wall Street analysts and wiped out billions in marke…
- Preoperative intravesical mitomycin C cuts NMIBC recurrence risk by 77% over five yearsA recent study evaluated giving two doses of intravesical mitomycin C before transurethral resection of bladder tumor (TURBT) in patients with non‑muscle‑invasive bladder cancer (NMIBC). Compared…